Objective To investigate the efficacy and safety of transurethral bladder submucosal injection of water for injection (WFI) combined with tumor resection in treating non-muscle invasive bladder cancer (NMIBC).
Methods A total of 91 non-muscle invasive bladder cancer patients meeting the inclusion criteria were randomly divided into treatment group and control group, with 45 cases per group. The treatment group underwent endoscopic injection of WFI around the tumor base whereas the control group was given routine electrotomy. All patients underwent regular intravesical instillation chemotherapy, routine cystoscopy and follow-up. The clinical basic characteristics, complications, and tumor recurrence were compared between the two groups.
Results There were no significant differences in age, gender, tumor site, size, staging, grading, and surgical costs between the two groups(P>0.05). There were 3 cases with obturator nerve reflex in treatment group, no perforation of bladder or anemia occurred. Therewere 5 cases with obturator nerve reflex in the control group, 1 case with bladder repair surgery due to perforation, and 1 case with blood transfusion due to anemia. The difference was not statistically significant (P>0.05). There were 2 cases with recurrence in treatment group, and 6 cases in the control group at 3 months after surgery, showing no significant difference(P>0.05). The treatment group had more recurrence patients than the control group at 6 months after surgery (15 vs. 6, P < 0.05). At 12 months after surgery, 7 patients were lost in follow-up, including 2 in the treatment group and 5 in the control group, and the treatment group had more recurrence patients than the control group(17 vs 7, P < 0.05).
Conclusion Endoscopic submucosal injection of WFI combined with tumor resection for NMIBC is safe, with less complications and lower recurrence rate.
DownLoad: